STOCKS TELEGRAPH

Author: ST Staff

  • Jounce Therapeutics Inc [JNCE] Rallies after Gilead Deal – What Next?

    Jounce Therapeutics Inc [JNCE] Rallies after Gilead Deal – What Next?

    Jounce Therapeutics Inc [NASDAQ:JNCE] is a top performer this afternoon. After trading in a range all through August, the stock has gapped up and is in gains of close to 50%.

    This follows the company’s announcement that it was entering into an exclusive license agreement with Gilead Sciences for a novel immunotherapy program named JTX-1811.  JTX-1811 is a monoclonal antibody that depletes immunosuppressive tumour-infiltrating T cells. It is currently under development and will have an investigational new drug application in H1 of 2020.

    Commenting on the agreement, between the two companies, Jounce CEO Richard Murray stated that the investment that Gilead’s had made in the JTX-1811 program was a major boost to the company’s translational science program that is differentiated and focuses on sustainability in treating people with cancer but have not gained from immunotherapy.

    He added that the company’s mission was to give patients the best immunotherapy treatments and that it remained focused on offering long-terms solutions such as JTX-1811. On his part, Gilead executive Vice President stated that they were happy to add JTX-`1811 to the company’s list of investigational immune-oncological treatments that have the capacity to improve the lives of cancer patients.

    He added that JTX-1811 was complementary to the company’s other treatment candidates for cancer, and that, it had the potential to become a new class of treatment for haematological malignancies’ as well as for the treatment of solid tumours.

    The excitement around this stock stems from the fact that the partnership with Gilead has validated the viability of the JTX-1811. Investors are expecting that the program will lead to a major breakthrough and add to Jounce revenues in the near-term.

    What next for Jounce

    Since the agreement hints at an IND application in H1 of 2021, there is bound to be a sustained interest in this stock until them. Any major breakthrough on the program could add to the momentum. Looking at it from the perspective of the overall market, the stock’s fundamentals could see it gain a massive boost from the increased positive sentiment in the market.

    If a COVID-19 vaccine is approved soon, there is likely to be a major rally in the equity markets, and high potential stocks like Jounce stand to gain the most. That momentum has already started building up, and if Jounce holds on to today’s gains, it could mark the beginning of a significant uptrend.

    About Jounce Therapeutics Inc

    Jounce Therapeutics Inc is an immunotherapy company that makes cancer treatments. The company is based in Cambridge, Massachusetts.

  • Stocks to Watch as Market Sentiment Points to a Good Day for Equities

    The markets are up this morning, with the NASDAQ leading the way. This has been driven by the increased momentum around big tech. More specifically, Apple and Tesla are the two key big tech stocks that are leading the way. The excitement comes from the news of the stock split itself and the fact that the two companies have recorded consistent growth all through the year. Besides big tech, there is increased optimism in the market banked on hopes that the worst of the pandemic is over. This is evident in the moves and investments that big companies are making. Yesterday, the markets woke up to the news that Nestle was buying Aimmune in a deal worth $2.6 billion. Similarly, companies are now confident enough to start doing mega IPOs. Today, Reuters has reported that Chindata, a Chinese data centre company was planning to do a $400 million IPO in the U.S. This would make it the 5th largest IPO of a Chinese company in the U.S in 2020. Such moves point to growing optimism in the market that the future is bright. As positive market sentiment grows, certain stocks that have positive news are outperforming the market. Some of the best performers ahead of markets are as below:

    Plus Therapeutics Inc [NASDAQ: PSTV]

    Plus Therapeutics Inc is a top performer this morning and is up by close to 50% pre-market.  This follows the company’s announcement that the U.S FDA had given it an orphan drug designation for Rhenium NanoLiposomes, an investigational drug for treating recurrent glioblastoma. The treatment is being developed with support from the NIH and NCI and is phase 1 dose-finding clinical trial. Commenting on the development, the company’s CEO, Dr. Marc Hedrick stated that the approval by the FDA was a key milestone towards the development of the treatment. He added that they believed the treatment has the potential to increase patient lifespans.

    Priority Technology Holdings Inc [NASDAQ: PRTH]

    Priority Technology Holdings Inc is another top performer this morning and is up by over 30% pre-market. This follows the company’s announcement that it had entered into an agreement with MRI software for the sale of its RentPayment™ business. Under the deal, MRI will buy the business that comprises of RentPayment.com™, DuesPayment.com™ and StorageRentPayment.com™. The deal also stipulates that Priority will provide its payment infrastructure as a service to the MRI platform.

    Athenex Inc [NASDAQ: ATNX]

    Athenex Inc is another top performer this morning and is up by over 20%. This follows the company’s announcement that the FD had accepted its NDA filing for its metastatic cancer treatments called Oral Paclitaxel and Encequidar. CEO Johnson Lau stated that they were happy with the milestone and continue making preparations for a commercial launch.

  • Here’s Why Peloton Interactive Inc. (NASDAQ: PTON) Stock Skyrocketed Today

    Peloton Interactive Inc. (NASDAQ: PTON), a provider of interactive fitness products is heading toward the new era of growth. The Goldman Sachs has uplifted the price target of Peloton Interactive from $84 to $96 on Wednesday, moving its shares to the record high-level and maintained a buy on Peloton.

    Heath Terry said that he believed that the fitness maker will beat the estimate of analysts and add new subscribers in Q4. Heath Terry forecasted that the Peloton will add 208,000 new subscribers while the Street is estimating that Peloton will add 199,000 new subscribers.

    Peloton Interactive Inc (NASDAQ: PTON) share price went from a low point around $17.70 to briefly over $77.46 in the past 52 weeks, though shares have since pulled back to $76.67. Peloton has gained +0.71 in the trading session on Monday. Peloton Interactive has traded up 33.16% from its 52-weeks low and traded down -1.01% from its 52-weeks high.

    Peloton has seen a sharp increase in the demands of its fitness services and products as customers now preferred to stay at home amid the COVID-19 pandemic. Peloton has made the addition of 176,600 paying subscribers in the Q3, representing the 64% YOY growth of the Company.

    Looking at its profitability, its return on investment (ROA) is 37.60%. Its Gross Margin is 44.90%. Moving towards its sales it has reported the sales of 1.44 billion. It had a trading volume of 15.74 million as compared to the average volume of roughly 7.64 million. Turing our focus on its liquidity, it has a current ratio of 3.30. Likewise, its quick ratio is 3.00. Peloton Interactive market capitalization has gained high, hitting $20.10 billion.

    Peloton Interactive, Inc. (PTON) was in 50 hedge funds’ portfolios at the end of June. The all-time high for these statistics is 48. The analyst also expected that the revenue will be $630.2 million in the QR of PTON. While Terry believes the revenue of PTON reaches $3.65 billion, $4.34 billion, and $6.03 billion over the next three FY respectively.

  • 15 Trending Stocks In Aerospace And Defense Industry To Invest In

    The Global Aerospace & Defense industry is undergoing continuous changes as it is striving to meet the increased demands. The demands for innovative technologies is likely to help the A&D recovered from the previous year. The global A&D has experienced a downfall in 2019.

    But 2020 is considered to be a year of significant milestones for the A&D sector as the industry is heading towards the new trajectory of innovation and growth. As the competition has been increasing amongst the leading global powers the focus is turned towards the development of next-generation changer technologies to improve the aerospace & defense sector.

    Let’s take a quick look at 15 leading companies in the aerospace and defense industry:

    Kratos Defense & Security Solutions Inc. (NASDAQ: KTOS)

    Kratos Defense & Security Solutions Inc. (KTOS) stock drop by -0.81% to $19.55. The most recent rating by The Benchmark Company, on March 18, 2020, is at a Buy. Kratos Defense & Security Solutions Inc. disclosed Thursday that the second flight of the X-61A Gremlins Air Vehicle (GAV) became a success. The flight was completed in just two hours. Kratos Defense & Security Solutions has recorded the 52-weeks low and high range of $5.00-$21.90, respectively. Its market cap has remained high, hitting $2.39 billion.

    Lockheed Martin Corporation (NYSE: LMT)

    Lockheed Martin Corporation (NYSE: LMT) Shares headed falling, lower as much as -1.35%. The most recent rating by RBC Capital Mkts, on May 21, 2020, is at a Sector perform. Lockheed Martin Corporation has recently won a $912 million deal to support the THAAD program. The contract has been awarded to Lockheed Martin Corporation by the Missile Defense Agency. Lockheed Martin shares went up 46.65% from its 52-weeks low and moved down -11.81% from its 52-weeks high.

    General Dynamics Corporation (NYSE: GD)

    General Dynamics Corporation (GD) last closed at $149.35, in a 52-week range of $100.55 to $193.76. Analysts have a consensus price target of $169.24. General Dynamics Corporation announced its joint venture with Spanish defense contractor Santa Bárbara Sistemas. GD had secured an $870 million worth of a contract from the Spanish Ministry for wheeled combat vehicles. The new deal is a part of a larger contract of $2.06 billion to supply 348 wheeled combat vehicles to the Spanish military. GD is up 48.53% from its 52-weeks low and down -22.92% from its 52-weeks high.

    Northrop Grumman Corporation (NYSE: NOC)

    Northrop Grumman Corporation (NYSE: NOC) last closed at $342.61, in a 52-week range of $263.31 to $385.01. It has traded up 30.12% from its 52-weeks low and traded down -11.01% from its 52-weeks high. Analysts have a consensus price target of $393.18. It has secured a $45 million deal involving UH-1Y and AH-1Z helicopters. The contract has been granted to Northrop by Naval Air Systems Command, Patuxent River, MD. The contract is anticipated to complete by December 2023.

    Raytheon Technologies Corporation (NYSE: RTX)

    Raytheon Technologies Corporation (NYSE: RTX) stock drop by -1.99% to $61.00. The most recent rating by Argus, on July 29, 2020, is at a Hold. Raytheon Technologies earlier disclosed it has won a $21.8 million contract to support the MALD flight vehicles. It has received the investment by the Air Force Life Cycle Management Center, Robins Air Force Base, GA. The Miniature Air Launched Decoy (MALD) is a small unmanned air-launched flight vehicle. It is manufactured to protect U.S. fighters and bombers from modern netted air defenses.

    The Boeing Company (NYSE: BA)

    The Boeing Company (NYSE: BA) Shares headed falling, lower as much as -2.26%. The most recent rating by Wolfe Research, on July 16, 2020, is at an Underperform. The Boeing Company’s 737 MAX jetliner has received the all-clear from Canadian Aviation Regulator Transport Canada. Boeing’s 737 MAX has been stopped services since mid-March 2019 after 346 people lost their lives in two fatal crashes within six months. The test result after Transport Canada Inspection raised hopes returning the jet to service. Boeing’s total market capitalization remained high, hitting $96.10 billion.

    Hexcel Corporation (NYSE: HXL)

    Hexcel Corporation (NYSE: HXL) stock drop by -5.02% to $39.39. The most recent rating by RBC Capital Mkts, on August 04, 2020, is at a Sector perform. Hexcel Corporation has reported the 2020 Q2 results. It has recorded net sales of $378.7 million and adjusted diluted EPS of $0.08 per share. As per the reports company’s second Gross margin for the Q2 was 14.5% compared to 27.7% in the prior-year period.

    AgEagle Aerial Systems Inc. (AMEX: UAVS)

    AgEagle Aerial Systems Inc. (AMEX: UAVS) shares were trading up 23.02% at $3.10 at the time of writing on Monday. AgEagle Aerial Systems Inc. (AMEX: UAVS) share price went from a low point around $0.19 to briefly over $5.15 in the past 52 weeks, though shares have since pulled back to $3.10. UAVS market cap has remained high, hitting $176.05M at the time of writing, giving it a price-to-sales ratio of more than 290.

    Virgin Galactic Holdings Inc. (NYSE: SPCE)

    Virgin Galactic Holdings Inc. (NYSE: SPCE) last closed at $17.90, in a 52-week range of $6.90 to $42.49. Analysts have a consensus price target of $27.00.

    Smith & Wesson Brands Inc. (NASDAQ: SWBI)

    Smith & Wesson Brands Inc. (NASDAQ: SWBI) stock soar by 1.19% to $18.26. The most recent rating by Cowen, on August 25, 2020, is at an Outperform.

    L3Harris Technologies Inc. (NYSE: LHX)

    L3Harris Technologies Inc. (NYSE: LHX) Shares headed rising, higher as much as 0.47%. The most recent rating by The Benchmark Company, on August 03, 2020, is at a Buy.

    Huntington Ingalls Industries Inc. (NYSE: HII)

    Huntington Ingalls Industries Inc. (NYSE: HII) fall -0.62% after losing more than -$0.94 on Monday. This company has a 52-weeks low and high range of $147.14-$279.71, respectively. It has moved up 2.98% from its 52-weeks low and moved down -45.83% from its 52-weeks high. HII has a total market capitalization of 6.17 billion.

    Textron Inc. (NYSE: TXT)

    Textron Inc. (NYSE: TXT) fall -1.35% after losing more than -$0.54 on Monday. It has a day low and a high range of $39.25-$40.00, respectively. Looking at its liquidity, it has a current ratio of 2.00. Its quick ratio is 1.00. Textron Inc.’s market capitalization has remained high, hitting 8.85 billion.

    Triumph Group Inc. (NYSE: TGI)

    Triumph Group Inc. (NYSE: TGI) fall -3.21% after losing more than -$0.24 on Monday. Triumph Group has recorded the 52-weeks low and high range of $3.02-$29.38, respectively. It has moved up 139.40% from ist 52-weeks low and moved down -75.39% from its 52-weeks low.

    Spirit AeroSystems Holdings Inc. (NYSE: SPR)

    Spirit AeroSystems Holdings Inc. (NYSE: SPR) last closed at $20.56, in a 52-week range of $13.69 to $92.81. Analysts have a consensus price target of $22.19. Looking at its liquidity, it has a current ratio of 2.70. Its quick ratio is 1.90. Spirit AeroSystems has a total market capitalization of 2.14 billion.

     

     

  • Here’s Top 25 Biotech Stocks For September 2020

    Here’s Top 25 Biotech Stocks For September 2020

    One thing constant in the world is change. As time passes there are many industries that are undergoing changes as they expand their businesses and bring new innovations. One of the industries that are known for their constant change is the biotechnology industry.

    The biotech industry is continuously changing in every aspect of daily existence with new technological breakthroughs and advancements in knowledge. Companies are constantly striving to bring new medicines and vaccines to deal with the diagnosis.

    Let’s have a look at the top 25 biotech companies which are continuously adding new trends in the market:

    Aimmune Therapeutics Inc. (NASDAQ: AIMT) shares were trading up 171.59% at $34.22 at the time of writing on Monday.

    Aimmune Therapeutics Inc. (NASDAQ: AIMT) share price went from a low point around $10.09 to briefly over $37.00 in the past 52 weeks, though shares have since pulled back to $34.22. AIMT market cap has remained high, hitting $2.13B at the time of writing, giving it a price-to-sales ratio of more than 3550.

    If we look at the recent analyst rating AIMT, Cowen initiated coverage on AIMT shares with an Outperform rating. Aimmune Therapeutics recently disclosed it has signed an agreement with Nestle S.A. As per the agreement, Nestle will pay $34.50 per share in an all-cash transaction.

    Akcea Therapeutics Inc. (AKCA) last closed at $18.28, in a 52-week range of $8.00 to $22.79. It has been disclosed yesterday that Ionis Pharmaceutical has bought the 24% shares of Akcea it hasn’t owned earlier for $18.15 per share in cash. This acquisition is one step forward to make a strong and efficient organization that gives benefits to all shareholders.

    Capricor Therapeutics Inc. (NASDAQ: CAPR) Shares headed rising, higher as much as 14.64% after Capricor Therapeutics to Present at The LD 500 Virtual Conference. Capricor market capitalization is 115.11 million. The most recent rating by Maxim Group, on December 26, 2018, is at a Hold.

    Capricor Therapeutics, a clinical-stage biotechnology company has disclosed earlier that the US Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for a Phase 2 clinical trial of CAP-1002 in COVID-19 patients.

    Apellis Pharmaceuticals Inc. (APLS) stock soar by 14.74% to $30.83. The most recent rating by ROTH Capital, on July 20, 2020, is at a Buy. Its stock fluctuated between the 52-weeks low range of $16.85 and a 52-weeks high range of $45.04. It has moved up 82.97% from its 52-weeks low and moved down -31.55% from its 52-weeks high.

    Xeris Pharmaceuticals Inc. (NASDAQ: XERS) rose 10.71% after gaining more than $0.45 on Monday. Xeris, a specialty pharmaceutical company disclosed August 26, 2020, that the Compensation Committee of Xeris’ Board of Directors awarded non-qualified stock options for an aggregate of 500 share of its common stock to 1 new employee under the Inducement Equity Plan of Xeris.

    Xeris share price went from a low point around $1.42 to briefly over $12.29 in the past 52 weeks, though shares have since pulled back to $4.71. It has traded up $231.34% from its 52-weeks low and has traded down -61.72% from its 52-weeks high.

    9 Meters Biopharma Inc. (NASDAQ: NMTR) shares headed rising, higher as much as 7.73%. It has disclosed Monday that it has decided to form the scientific advisory board (SAB). The SAB includes an acclaimed group of six experts in the gastroenterology field with sub-specialties in celiac disease, inflammatory bowel disease (IBD), and functional GI diseases. 9 Meters have gained +0.05 during its trading on Monday. It has moved up 76.17% and moved down -49.46% from its 52-weeks low and high range, respectively.

    VBI Vaccines Inc. (NASDAQ: VBIV) rose 6.77% after gaining more than $0.27 on Monday. VBI Vaccines Presents Phase 3 Sci-B-Vac® Data at EASL 2020. During the presentation, Professor of Paediatrics at the University of Bristol, UK, and principal investigator of the CONSTANT Phase 3 clinical study, Adam Finn, M.D., Ph.D., revealed the encouraging points of hepatitis B antibodies. VBI Vaccines traded up 815.15% from its 52-weeks low and traded down -38.53% from its 52-weeks high.

    CymaBay Therapeutics Inc. (NASDAQ: CBAY) rose 5.37% after gaining more than $0.33 on Monday. It has disclosed the result of Phase 2 study of seladelpar in patients with primary biliary cholangitis (PBC). The data presented at electronic presentation showed the safety and efficacy of seladelpar over 1 year of open level treatment. These findings suggest that seladelpar treatment in a high-risk PBC patient population promotes clinically significant improvement.

    BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) rose 4.53% after gaining more than $0.18 on Monday. BioCryst Inc disclosed Monday it has received Orphan Drug Desigantion from FDA for its oral Factor D inhibitor, BCX9930. It is used for the treatment paroxysmal nocturnal hemoglobinuria (PNH). It has moved up as its announced it has received the $44 million  National Institute of Allergy and Infectious Diseases (NIAID). This amount is awarded to BCRX by NIAID to support the development of galidesivir.

    ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) Shares headed rising, higher as much as 4.24%. The most recent rating by Raymond James, on August 25, 2020, is at an Outperform. ACADIA Inc has announced earlier that it has bought CerSci Therapeutics.

    Immunomedics Inc. (IMMU) stock soar by 6.37% to $44.56. The most recent rating by Barclays, on May 05, 2020, is at an Overweight. Immunomedics stock has fluctuated between the 52-weeks low and high range of $8.80-$44.91, respectively.

    Alexion Pharmaceuticals Inc. (NASDAQ: ALXN) last closed at $114.22, in a 52-week range of $72.67 to $121.50. Analysts have a consensus price target of $141.47.

    Seres Therapeutics Inc. (NASDAQ: MCRB) stock soar by 8.21% to $26.49.  It has moved upward 951.19% from its 52-weeks low and moved down -19.73% from its 52-weeks high. The most recent rating by Piper Sandler, on August 18, 2020, is at an Overweight.

    Rhythm Pharmaceuticals Inc. (NASDAQ: RYTM) last closed at $29.51 after gaining +2.54 on Monday. It has a 52-week range of $12.99 to $27.97. It has moved up 127.17% and 5.51% from its 52-weeks low and high, respectively. Analysts have a consensus price target of $32.88.

    Geron Corporation (NASDAQ: GERN) Shares headed rising, higher as much as 6.22%. The most recent rating by Stifel, on August 03, 2020, is at a Buy.

    Sesen Bio Inc. (NASDAQ: SESN) rose 6.19% after gaining more than $0.06 on Monday. SESN’s stock has changed between the 52-weeks low range of $0.37 and a high range of $1.52. It has moved up and moved down 178.38%, -33.12% from its 52-weeks low and high, respectively.

    Kadmon Holdings Inc. (NYSE: KDMN) last closed at $5.00, in a 52-week range of $2.04 to $5.50. It has traded up 145.10% from its 52-weeks low and traded down -9.09% from its 52-weeks high. Looking at its liquidity, its current ratio is 6.20.

    Evofem Biosciences Inc. (EVFM) stock soar by 6.07% to $3.32 after Evofem Biosciences to Participate in Four Upcoming Investor Conferences. The most recent rating by Morgan Stanley, on August 20, 2020, is at an Equal-weight.

    MacroGenics Inc. (NASDAQ: MGNX) Shares headed rising, higher as much as 6.01%. The most recent rating by Citigroup, on August 03, 2020, is at a Neutral.

    Iovance Biotherapeutics Inc. (NASDAQ: IOVA) last closed at $33.33, in a 52-week range of $17.67 to $41.49. Analysts have a consensus price target of $47.08.

    Surface Oncology Inc. (NASDAQ: SURF) stock soar by 5.01% to $6.50. The most recent rating by Wedbush, on August 28, 2020, is at an Outperform.

    Fortress Biotech Inc. (NASDAQ: FBIO) Shares headed rising, higher as much as 4.63% after LD Micro — 360 Companies Set to Present this Week. The most recent rating by B. Riley FBR, on December 18, 2019, is at a Buy.

    Synthetic Biologics Inc. (SYN) last closed at $0.64, in a 52-week range of $0.25 to $0.75. It has moved up 153.17% from its 52-weeks low and moved down -14.87% from its 52-weeks high.

    Zogenix Inc. (NASDAQ: ZGNX) stock soar by 4.37% to $23.67. The most recent rating by Raymond James, on August 25, 2020, is at an Mkt perform. ZGNX has traded up and down 42.16% and -58.63% from its 52-weeks low and high range.

    Dynavax Technologies Corporation (NASDAQ: DVAX) rose 4.18% after gaining more than $0.24 on Monday. Dynavax to Present at the H.C. Wainwright Virtual 22nd Annual Global Investment Conference.

     

  • Which One is Better After Stock Split: TSLA or AAPL?

    Which One is Better After Stock Split: TSLA or AAPL?

    It is a good day for Tesla [NASDAQ: TSLA] and Apple [NASDAQ:AAPL] investors. The two companies have done a stock split to become accessible to a wider investor base. Investor momentum in the two is being driven by the excitement around the stock split and the fact that they are both fundamentally strong companies. Tesla has turned profitable and continues to record strong revenue numbers.

    Apple Inc [AAPL] too is on a growth trajectory and has made history by hitting a valuation of $2 trillion. So between these two companies, which one is a better hold?

    Well, the two stocks are a good hold both for short-term and long-term investing.  As such with enough resources, holding both presents a good opportunity for gains.

    However, if one only has the resources to invest in one of the two stocks, AAPL would be a better hold. That’s because, it is a dominant player in its markets, with little possibility of being overtaken by any other company.  For context, Apple dominates 50% of the smartwatch market.

    The company’s core product, the iPhone is one of the fastest-selling smartphones in the market. Most importantly, the iPhone stands out for the margins it makes per phone. The company sells the phones at a premium and is the key reason behind Apple’s huge valuation. Going by the iPhone’s brand equity, it is unlikely to be dethroned by any other smartphone maker anytime soon.

    On top of that, the company has been able to leverage the iPhone to sell a wide array of profitable products. Apple enjoys a near duopoly with Google in the Apps market. The Apple store is a major revenue driver for Apple.

    This is evident in its recent tussle with Fortnite over the commissions that the company charges. Despite the high commissions it charges, the company has the market power to dictate terms as was seen in its ability to kick out Fortnite, a major gaming company from its platform.

    Looking into the future, Apple stands to benefit from the upcoming 5G networks. 5G will unlock a new wave of applications for the iPhone, creating a new growth cycle for the company. This makes AAPL a viable stock to hold long-term.

    Tesla has its strengths but its biggest risk is competition. As the large carmakers such as Toyota and Volkswagen enter the electric car space more aggressively, Tesla’s growth curve could flatten. Nonetheless, the company is investing heavily in R&D and will remain a major player in the electric car market going forward.

  • Here’s 10 Trending Stocks in Software – Infrastructure Industry

    Here’s 10 Trending Stocks in Software – Infrastructure Industry

    Tech stocks have been on fire lately. It appears that they continue hitting new record-breaking highs, for quite a while. Software is everywhere & considered to be the focal point of business innovation lately. The software industry made progress rapidly. The primary mode of software deployment has moved from legacy on-premise to cloud architecture with SaaS considered to be the preferred delivery mode.

    A number of significant organizations are running on Software and provided as online services from movies to agriculture, etc. Tech stocks keep pushing new highs as time passes. A number of silicon-valley styles entrepreneurial tech companies are winning the race.

    Here some of the booming software infrastructure stocks you should add to your list.

    Nutanix Inc. (NASDAQ: NTNX) shares were trading up 29.17% at $28.03 at the time of writing on Friday. Nutanix Inc. (NASDAQ: NTNX) share price went from a low point around $11.31 to briefly over $37.86 in the past 52 weeks, though shares have since pulled back to $28.03. NTNX market cap has remained high, hitting $4.33B at the time of writing, giving it a price-to-sales ratio of more than 3.

    If we look at the recent analyst rating NTNX, Robert W. Baird downgraded coverage on NTNX shares with a Neutral rating and a $28.71 price target, which implies room for 0.68% upside momentum this year.

    Microsoft Corporation (NASDAQ: MSFT) last closed at $228.91, in a 52-week range of $132.52 to $231.15. Analysts have a consensus price target of $226.93.

    Oracle Corporation (NYSE: ORCL) stock soar by 1.22% to $57.88. The most recent rating by Argus, on June 19, 2020, is at a Hold. Oracle saw a positive change in its earning growth and has been doing great lately compares to other companies that have been seeing a negative change in its growth.

    Square Inc. (NYSE: SQ) Shares headed rising, higher as much as 0.21%. The most recent rating by Mizuho, on August 27, 2020, is at a Buy.

    Dropbox Inc. (NASDAQ: DBX) rose 2.02% after gaining more than $0.41 on Friday. Dropbox, Inc saw a sharp increase in its share price movements in the recent months.

    NortonLifeLock Inc. (NASDAQ: NLOK) last closed at $24.05, in a 52-week range of $13.02 to $24.40. Analysts have a consensus price target of $24.33.

    BlackBerry Limited (NYSE: BB) stock soar by 3.98% to $5.23. The most recent rating by TD Securities, on April 01, 2020, is at a Hold.  BlackBerry (NYSE: BB) announced the Redemption of Existing Convertible Debentures. BlackBerry has given the notice of redemption to all holders of the 3.75% debentures. BB set the outstanding principal amount of the 3.75% Debentures is US$605 million.

    Okta Inc. (NASDAQ: OKTA) Shares headed falling, lower as much as -4.79%. The most recent rating by RBC Capital Mkts, on July 06, 2020, is at an Outperform. The return on capital employed ratio of Okta Inc. has disclosed that the current assets of the company are not helping it achieving higher returns.

    Box Inc. (NYSE: BOX) fall -1.19% after losing more than -$0.24 on Friday. Box, Inc. aimed to develop a solution and strived to build a platform that engaged in managing the content in the cloud.  The company has disclosed the stellar Q2 2021 earnings report. It has reported the revenue of US 1992.3 million. Its revenue beat analysts expectation as its recorded the 11%rise in Q2 revenue.

    CrowdStrike Holdings Inc. (NASDAQ: CRWD) last closed at $118.64, in a 52-week range of $31.95 to $119.94. Analysts have a consensus price target of $112.67. The stock of CrowdStrike Holdings has moved up more than 30% over the past 12 months. Its revenue rose 85% last quarter with the increase of its subscribers base.

     

  • Stocks to watch as Market Sentiment Turns Positive Amidst a Drop in Uncertainty

    Stocks to watch as Market Sentiment Turns Positive Amidst a Drop in Uncertainty

    The markets are upbeat this morning with the S&P 500, the Dow and the NASDAQ all in the green. This comes amidst analysts’ projections that the uncertainty that characterized the market since March is easing up. When the COVID-19 lockdowns started, the markets entered into deep uncertainty with corporations suspending their projections for future earnings.

    However, this has since changed. Many companies are now offering favourable projections for the rest of the year. Many of them have also proven to be quite resilient and reported strong earnings over the last quarter. With the lockdowns now easing up in the U.S and worldwide, optimism is high that the economy will rebound.

    The optimism is further enhanced by the fact that biotech companies, and research institutions, working on a COVID-19 vaccine are giving positive pointers to a possible vaccine before the end of the year.

    Treatments are also coming up, and the U.S FDA has already approved the use of plasma in the treatment of COVID-19 citing its high efficiency. In this environment of high optimism in the U.S economy, stocks that have good news around them this morning are gaining exponentially. Some of the biggest stock gainers this morning are:

    Aimmune Therapeutics Inc [NASDAQ: AIMT]

    Aimmune Therapeutics Inc is a top performer this morning and is up by over 160%. This follows news that Nestle had agreed to buy the company in a $2.6 billion deal. Under the deal, Nestle will buy the company at $34.50 per share, representing a premium compared to the stock’s trading price of $12.60 as of Friday’s close.

    In a statement, Nestle stated that Aimmune’s Palforzia is the world’s first and only FDA-approved treatment for peanut reactions in children aged between the ages of four and seventeen. Prior to the takeover, Nestle already owned 26% of Aimmune.

    Transatlantic Petroleum Ltd [NYSE: TAT]

    Transatlantic Petroleum Ltd is another top performer this morning and is up by 33%. This follows the company’s announcement that its shareholders had approved the payment of dividends on the company’s series A preferred common stock.

    The dividends are payable on the 15th of September 2020.  This has triggered optimism in the company’s health and hence the current price rally ahead of the upcoming earnings season.

    Vivopower International PLC [NASDAQ: VVPR]

    Vivopower International PLC is another stock showing lots of potential in early morning trading. After a massive rally on Friday that saw it close the day with gains of 69%, the stock is in the green pre-market. It’s momentum today is price action driven days after the company reported unaudited results showing revenue growth of 12% for the year ending  30th June 2020.

     

  • Aimmune Therapeutics [NASDAQ: AIMT] Signs Definitive Agreement With Nestle

    Aimmune Therapeutics [NASDAQ: AIMT] Signs Definitive Agreement With Nestle

    Aimmune Therapeutics, Inc. [NASDAQ: AIMT] disclosed today it has signed a definitive agreement with a wholly-owned subsidiary of Nestle S.A, Sociétés des Produits Nestlé S.A.  Sociétés des Produits Nestlé S.A to purchase Aimmune for $34.50 per share in an all-cash transaction representing the total equity value of $2.6 billion, as per the agreement.

    All the members of the board of directors of Aimmune were agreed to the agreement. Through this acquisition, both the firms will be able to create a world leader in food allergy prevention and treatment. Aimmune Therapeutics and Nestle S.A both aimed to change the lives of people around the world living with food allergies.

    Aimmune Therapeutic traded up 171.03% at $34.15 during the pre-market trading session after its agreement with Nestle S.A. AIMT had a trading volume of 1.89 million as compared to the average volume of 1.11 million.

    It has earlier closed at $12.60 and up 5.09% during its last trading session of Friday. It has recorded the day low range of $11.82 and a day high range of $12.68.

    In the past 52-weeks of trading, this company’s stock has fluctuated between the low of $10.09 and a high of $37.00. Aimmune moved up 24.88% and moved down -65.95% from its 52-weeks low and high. Focusing on its profitability, its return on assets (ROA) is -92.70%, and return on equity (ROE) is -170.90%.

    Turing our focus on its liquidity, it has a current ratio of 7.50 and its quick ratio is 7.40. Aimmune Therapeutics has a total market capitalization of 784.73 million. It has reported the sales of 0.60 million.

    Until the completion of the transaction, Aimmune will work as an independent firm. Looking at the transaction details, Nestle S.A will start a tender offer to buy all the outstanding shares of AIMT. After the completion of the tender offer, Nestle will start the merger of Aimmune with a subsidiary of SPN.

    PALFORZIA of Aimmune is the first official treatment for peanut allergy. Palforiza is the first health product which has significant sale potential. The deal between Aimmune and SPN is anticipated to conclude in the fourth quarter of 2020.

  • FSD Pharma [NASDAQ: HUGE] Decides To File IND For FSD201 To Treat COVID-19 Patients

    FSD Pharma [NASDAQ: HUGE] Decides To File IND For FSD201 To Treat COVID-19 Patients

    FSD Pharma Inc. [NASDAQ: HUGE] has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) to gain approval for the use of FSD201 to treat COVID-19 patients, the company disclosed today.

    FSD201 has anti-inflammatory properties that are proven to be useful to avoid cytokines storm linked with acute lung injury in hospitalized COVID-19 patients.

    FSD share traded up 6.23% during the trading session of Friday. This company has an opening price of $3.04 and closed at $3.24. HUGE has a day low and high range of $3.00-$3.25, respectively.

    It had a trading volume of 475.46K as compared to the average volume of roughly 932.84K. This company has a total market capitalization of 42.06 million.

    In the past 52-weeks of trading, this company’s stock has fluctuated between the low of $2.39 and a high of $17.49. Its shares traded up 35.56% from its 52-weeks low and traded down -81.47% from its 52-weeks high.

    The FSD201 COVID-19 trail will be conducted at 25-30 sites to check the safety and efficacy of FSD201. Furthermore, the Board of Directors has given the official approval regarding the issuance of additional 369,255 class B subordinate voting shares to certain of the directors, officers, employees, and consultants of the company. This step is taken to provide the share-based compensation.

    Additionally, it is also disclosed that Dr. Raza Bokhari has got 805,802 Class B Shares instead of cash compensation for his services as CEO and Executive Co-Chairman of the Company. Dr. Bokhari has now gained ownership of approx. 8.5% of issued and outstanding class B shares. He also has control over  33.3% of the outstanding Class A multiple voting shares of the company.